CA
RPRX icon

Clearstead Advisors’s Royalty Pharma RPRX Stock Holding History

Clearstead Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Buy
451
+404
+860% +$21K ﹤0.01% 1730
2026
Q1 		$2.25K Sell
47
-40
-46% -$1.75K ﹤0.01% 1875
2025
Q4 		$3.36K Buy
87
+47
+118% +$1.79K ﹤0.01% 2086
2025
Q3 		$1.41K Buy
40
+37
+1,233% +$1.34K ﹤0.01% 2554
2025
Q2 		$109 Sell
3
-12
-80% -$398 ﹤0.01% 2613
2025
Q1 		$467 Buy
+15
New +$475 ﹤0.01% 2077

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's RPRX Position: Q2 2026 in Review

Clearstead Advisors increased its Royalty Pharma (RPRX) stake by 860% in Q2 2026, buying an estimated $21K and bringing the position to 451 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

Clearstead Advisors first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Clearstead Advisors held 451 shares of Royalty Pharma worth $25.3K as of Q2 2026.
  • Clearstead Advisors bought 404 Royalty Pharma shares in Q2 2026, an estimated $21K.
  • Royalty Pharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1730 holding.
  • Clearstead Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.